Newron Pharmaceuticals S.p.A. Stock Deutsche Boerse AG
Stocks
NP5
IT0004147952
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.60 EUR | +4.13% |
|
-.--% | -52.72% |
| 07-03 | Newron Pharmaceuticals to Make Changes to Phase 3 Trial of Schizophrenia Treatment | MT |
| 05-05 | Edison Is Not Overly Concerned About a Trial Suspension |  |
| Market Cap | 261M 300M 243M 223M 421M 28.65B 428M 2.86B 1.12B 14.28B 1.13B 1.1B 47.3B | P/E 2026 * |
-9.23x | P/E 2027 * | 33.9x |
|---|---|---|---|---|---|
| Enterprise Value | 299M 345M 279M 256M 484M 32.9B 491M 3.28B 1.29B 16.39B 1.3B 1.27B 54.32B | EV / Sales 2026 * |
27.6x | EV / Sales 2027 * | 6.14x |
| Free-Float |
86.89% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Newron Pharmaceuticals S.p.A.
| 1 day | +4.13% | ||
| 1 month | -9.68% | ||
| 3 months | -22.46% | ||
| 6 months | -42.20% | ||
| Current year | -52.72% |
| 1 week | 12.1 |  | 12.7 |
| 1 month | 12.05 | | 13.9 |
| Current year | 12.05 | | 33.55 |
| 1 year | 7.01 | | 33.55 |
| 3 years | 4.2 | | 33.55 |
| 5 years | 1 | | 33.55 |
| 10 years | 1 | | 33.55 |
| Manager | Title | Age | Since |
|---|---|---|---|
Stefan Weber
CEO | Chief Executive Officer | 62 | 2012-05-14 |
Roberto Galli
DFI | Director of Finance/CFO | - | 2011-12-31 |
Filippo Moriggia
COO | Chief Operating Officer | - | 2021-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Stefan Weber
BRD | Director/Board Member | 62 | 2012-05-14 |
Gillian Dines
BRD | Director/Board Member | - | 2023-03-31 |
Margarita Chavez
BRD | Director/Board Member | - | 2024-04-16 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.13% | -.--% | - | - | 300M | |
| -1.40% | +2.59% | -1.71% | +11.28% | 48.53B | |
| -2.41% | -0.90% | +411.96% | +495.33% | 39.87B | |
| -1.16% | +12.96% | +28.81% | +7.25% | 38.68B | |
| -1.88% | -3.03% | +5.69% | +53.00% | 35.13B | |
| -1.74% | +5.12% | +9.58% | +46.02% | 29.79B | |
| -2.85% | -3.92% | - | - | 16.08B | |
| -0.21% | -4.04% | +36.40% | +125.75% | 16.11B | |
| -0.64% | +2.65% | +3.40% | +13.11% | 13.61B | |
| -1.19% | -1.32% | -1.73% | -34.37% | 12.62B | |
| Average | -0.93% | +0.82% | +61.55% | +89.67% | 27.82B | |
| Weighted average by Cap. | -1.59% | +1.63% | +79.16% | +109.15% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 10.84M 12.5M 10.09M 9.27M 17.52M 1.19B 17.79M 119M 46.72M 594M 46.94M 45.9M 1.97B | 44.83M 51.68M 41.72M 38.33M 72.43M 4.93B 73.57M 492M 193M 2.46B 194M 190M 8.14B |
| Net income | -31.17M -35.94M -29.01M -26.66M -50.37M -3.43B -51.16M -342M -134M -1.71B -135M -132M -5.66B | 5.02M 5.79M 4.67M 4.3M 8.12M 552M 8.24M 55.11M 21.64M 275M 21.74M 21.27M 912M |
| Net Debt | 38.68M 44.59M 36M 33.08M 62.5M 4.25B 63.48M 424M 167M 2.12B 167M 164M 7.02B | 14.72M 16.97M 13.7M 12.58M 23.78M 1.62B 24.15M 161M 63.41M 806M 63.71M 62.3M 2.67B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-31 | €12.60 | +4.13% | 0 |
| 26-07-30 | €12.10 | -4.72% | 0 |
| 26-07-29 | €12.70 | +0.79% | 0 |
| 26-07-28 | €12.60 | -0.79% | 0 |
| 26-07-27 | €12.70 | +0.79% | 0 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- NWRN Stock
- NP5 Stock
Select your edition
All financial news and data tailored to specific country editions
